When it comes to which patients receive biologic therapies for psoriasis, language proficiency may be a factor. Results of a medical expenditure survey (J Dermatolog Treat. 2020 Sep 14;1-5) of more than four million US patients with psoriasis show that those with higher English proficiency are 61 times more likely to access biologics. Researchers found that 97.4 percent of those who received biologics had perfect English proficiency.
Multivariate logistic regression found that patients with less than perfect English proficiency were significantly less likely to have access to biologics, after adjusting for insurance status, income, education, healthcare utilization, and other sociodemographic and clinical factors.